Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Dec;83(12):1607–1611. doi: 10.1054/bjoc.2000.1496

Application of positron emission tomography imaging to cancer screening

S Yasuda 1,2, M Ide 1, H Fujii 1, T Nakahara 1, Y Mochizuki 1,2, W Takahashi 1, A Shohtsu 1
PMCID: PMC2363454  PMID: 11104553

Abstract

Whole-body positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) is a diagnostic modality that can noninvasively survey the entire body and sensitively detect various cancers. In this study, we examined the potential application of whole-body PET for cancer screening in asymptomatic individuals. PET was performed in conjunction with conventional examinations including physical examination, laboratory study, ultrasonography and chest computed tomography. Between September 1994 and March 1999, 3165 asymptomatic individuals participated in 5575 screening sessions (2017 men and 1148 women; mean ± SD age, 52.2 ± 10.4 years). Follow-up periods were no less than 10 months. PET results were compared with the screening outcomes. Within 1 year after screening, malignant tumours were discovered in 67 of the 3165 participants (2.1%). PET findings were true-positive in 36 of the 67 cancers (54%). Most of the 36 patients underwent potentially curative surgery; thus a wide variety of cancers were detected by PET at potentially curable stages. However, PET findings were false-negative in 31 of the 67 patients (46%). 14 of these 31 (45%) were of urological origin. FDG PET imaging has the potential to detect a wide variety of cancers at potentially curable stages. However, PET imaging is not suited to screening test of general population because PET examination involves substantial cost. © 2000 Cancer Research Campaign http://www.bjcancer.com

Keywords: PET, FDG, tumour imaging, glucose metabolism, cancer screening

Full Text

The Full Text of this article is available as a PDF (111.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adler L. P., Blair H. F., Makley J. T., Williams R. P., Joyce M. J., Leisure G., al-Kaisi N., Miraldi F. Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med. 1991 Aug;32(8):1508–1512. [PubMed] [Google Scholar]
  2. Conti P. S., Lilien D. L., Hawley K., Keppler J., Grafton S. T., Bading J. R. PET and [18F]-FDG in oncology: a clinical update. Nucl Med Biol. 1996 Aug;23(6):717–735. doi: 10.1016/0969-8051(96)00074-1. [DOI] [PubMed] [Google Scholar]
  3. Delbeke D. Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma. J Nucl Med. 1999 Apr;40(4):591–603. [PubMed] [Google Scholar]
  4. Engel H., Steinert H., Buck A., Berthold T., Huch Böni R. A., von Schulthess G. K. Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulations. J Nucl Med. 1996 Mar;37(3):441–446. [PubMed] [Google Scholar]
  5. Henschke C. I., McCauley D. I., Yankelevitz D. F., Naidich D. P., McGuinness G., Miettinen O. S., Libby D. M., Pasmantier M. W., Koizumi J., Altorki N. K. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet. 1999 Jul 10;354(9173):99–105. doi: 10.1016/S0140-6736(99)06093-6. [DOI] [PubMed] [Google Scholar]
  6. Higashi T., Tamaki N., Torizuka T., Nakamoto Y., Sakahara H., Kimura T., Honda T., Inokuma T., Katsushima S., Ohshio G. FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors. J Nucl Med. 1998 Oct;39(10):1727–1735. [PubMed] [Google Scholar]
  7. Hulka B. S. Cancer screening. Degrees of proof and practical application. Cancer. 1988 Oct 15;62(8 Suppl):1776–1780. doi: 10.1002/1097-0142(19881015)62:1+<1776::aid-cncr2820621314>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  8. Jones S. C., Alavi A., Christman D., Montanez I., Wolf A. P., Reivich M. The radiation dosimetry of 2 [F-18]fluoro-2-deoxy-D-glucose in man. J Nucl Med. 1982 Jul;23(7):613–617. [PubMed] [Google Scholar]
  9. Kaneko M., Eguchi K., Ohmatsu H., Kakinuma R., Naruke T., Suemasu K., Moriyama N. Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography. Radiology. 1996 Dec;201(3):798–802. doi: 10.1148/radiology.201.3.8939234. [DOI] [PubMed] [Google Scholar]
  10. Kramer B. S., Gohagan J., Prorok P. C. NIH Consensus 1994: screening. Gynecol Oncol. 1994 Dec;55(3 Pt 2):S20–S21. doi: 10.1006/gyno.1994.1335. [DOI] [PubMed] [Google Scholar]
  11. Lassen U., Daugaard G., Eigtved A., Damgaard K., Friberg L. 18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT). Eur J Cancer. 1999 Jul;35(7):1076–1082. doi: 10.1016/s0959-8049(99)00077-5. [DOI] [PubMed] [Google Scholar]
  12. Macura K. J., Burke G., Robinson V. J. Osteogenic sarcoma associated with the Rothmund-Thomson syndrome. Clin Nucl Med. 1998 Feb;23(2):116–118. doi: 10.1097/00003072-199802000-00017. [DOI] [PubMed] [Google Scholar]
  13. Mejia A. A., Nakamura T., Masatoshi I., Hatazawa J., Masaki M., Watanuki S. Estimation of absorbed doses in humans due to intravenous administration of fluorine-18-fluorodeoxyglucose in PET studies. J Nucl Med. 1991 Apr;32(4):699–706. [PubMed] [Google Scholar]
  14. Miraldi F., Vesselle H., Faulhaber P. F., Adler L. P., Leisure G. P. Elimination of artifactual accumulation of FDG in PET imaging of colorectal cancer. Clin Nucl Med. 1998 Jan;23(1):3–7. doi: 10.1097/00003072-199801000-00002. [DOI] [PubMed] [Google Scholar]
  15. Nakata B., Chung Y. S., Nishimura S., Nishihara T., Sakurai Y., Sawada T., Okamura T., Kawabe J., Ochi H., Sowa M. 18F-fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma. Cancer. 1997 Feb 15;79(4):695–699. [PubMed] [Google Scholar]
  16. Nishizawa K., Maruyama T., Takayama M., Iwai K., Furuya Y. [Estimation of effective dose from CT examination]. Nihon Igaku Hoshasen Gakkai Zasshi. 1995 Sep;55(11):763–768. [PubMed] [Google Scholar]
  17. Okada J., Oonishi H., Yoshikawa K., Itami J., Uno K., Imaseki K., Arimizu N. FDG-PET for predicting the prognosis of malignant lymphoma. Ann Nucl Med. 1994 Aug;8(3):187–191. doi: 10.1007/BF03164996. [DOI] [PubMed] [Google Scholar]
  18. Oshida M., Uno K., Suzuki M., Nagashima T., Hashimoto H., Yagata H., Shishikura T., Imazeki K., Nakajima N. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-D-glucose. Cancer. 1998 Jun 1;82(11):2227–2234. [PubMed] [Google Scholar]
  19. Price P., Jones T. Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? The EC PET Oncology Concerted Action and the EORTC PET Study Group. Eur J Cancer. 1995 Nov;31A(12):1924–1927. doi: 10.1016/0959-8049(95)00421-1. [DOI] [PubMed] [Google Scholar]
  20. Rigo P., Paulus P., Kaschten B. J., Hustinx R., Bury T., Jerusalem G., Benoit T., Foidart-Willems J. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med. 1996 Dec;23(12):1641–1674. doi: 10.1007/BF01249629. [DOI] [PubMed] [Google Scholar]
  21. Robert G., Milne R. A Delphi study to establish national cost-effectiveness research priorities for positron emission tomography. Eur J Radiol. 1999 Apr;30(1):54–60. doi: 10.1016/s0720-048x(98)00139-9. [DOI] [PubMed] [Google Scholar]
  22. Taubes G. The breast-screening brawl. Science. 1997 Feb 21;275(5303):1056–1059. doi: 10.1126/science.275.5303.1056. [DOI] [PubMed] [Google Scholar]
  23. Yasuda S., Kubota M., Tajima T., Tajima T., Umemura S., Fujii H., Takahashi W., Ide M., Shohtsu A. A small breast cancer detected by PET. Jpn J Clin Oncol. 1999 Aug;29(8):387–389. doi: 10.1093/jjco/29.8.387. [DOI] [PubMed] [Google Scholar]
  24. Yasuda S., Shohtsu A. Cancer screening with whole-body 18F-fluorodeoxyglucose positron-emission tomography. Lancet. 1997 Dec 20;350(9094):1819–1819. doi: 10.1016/s0140-6736(97)24051-1. [DOI] [PubMed] [Google Scholar]
  25. Yasuda S., Shohtsu A., Ide M., Takagi S., Takahashi W., Suzuki Y., Horiuchi M. Chronic thyroiditis: diffuse uptake of FDG at PET. Radiology. 1998 Jun;207(3):775–778. doi: 10.1148/radiology.207.3.9609903. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES